{
    "clinical_study": {
        "@rank": "46770", 
        "arm_group": [
            {
                "arm_group_label": "MenACYW Vaccine Group", 
                "arm_group_type": "Experimental", 
                "description": "Participants who receive MenACYW conjugate vaccine"
            }, 
            {
                "arm_group_label": "Menomune\u00ae  A/C/Y/W 135 Vaccine Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will receive Menomune\u00ae A/C/Y/W 135 Vaccine"
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objectives:\n\n        -  To describe the antibody responses to meningococcal serogroups A, C, Y, and W-135,\n           measured by serum bactericidal assay using human complement (hSBA) and baby rabbit\n           complement (SBA-BR), induced by a single dose of MenACYW conjugate vaccine or Menomune\u00ae\n           - A/C/Y/W-135.\n\n        -  To describe the safety profile of a single dose of MenACYW conjugate vaccine or\n           Menomune\u00ae - A/C/Y/W-135."
        }, 
        "brief_title": "Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Meningitis", 
            "Meningococcal Meningitis", 
            "Meningococcal Infections", 
            "Invasive Meningococcal Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningitis, Meningococcal", 
                "Meningococcal Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "All participants will receive a single dose of their assigned vaccine on Day 0. They will be\n      assessed for immunogenicity on Day 30, and monitored for safety throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged 56 or older on the day of inclusion\n\n          -  Informed consent form has been signed and dated\n\n          -  Able to attend all scheduled visits and to comply with all trial procedures.\n             Exclusion Criteria:\n\n          -  Subject is pregnant, or lactating, or of childbearing potential (to be considered of\n             non-childbearing potential, a female must be post-menopausal for at least 1 year,\n             surgically sterile, or using an effective method of contraception or abstinence from\n             at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination)\n\n          -  Participation at the time of study enrollment (or in the 4 weeks preceding the trial\n             vaccination) or planned participation during the present trial period in another\n             clinical trial investigating a vaccine, drug, medical device, or medical procedure\n\n          -  Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned\n             receipt of any vaccine in the 4 weeks following the trial vaccination except for\n             influenza vaccination, which may be received at least 2 weeks before or after the\n             study vaccines\n\n          -  Previous vaccination against meningococcal disease with either a trial vaccine or\n             another vaccine\n\n          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,\n             within the preceding 6 months; or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n\n          -  History of meningococcal infection, confirmed either clinically, serologically, or\n             microbiologically\n\n          -  At high risk for meningococcal infection during the trial\n\n          -  Known systemic hypersensitivity to latex or any of the vaccine components, or history\n             of a severe reaction to the vaccines used in the trial or to a vaccine containing any\n             of the same substances\n\n          -  Personal history of Guillain-Barr\u00e9 syndrome\n\n          -  Personal history of an Arthus-like reaction after vaccination with a tetanus\n             toxoid-containing vaccine within at least 10 years of the proposed study vaccination\n\n          -  Self-reported thrombocytopenia, contraindicating intramuscular vaccination\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating intramuscular vaccination\n\n          -  Deprived of freedom by an administrative or court order, or in an emergency setting,\n             or hospitalized involuntarily\n\n          -  Current alcohol abuse or drug addiction\n\n          -  Chronic illness that, in the opinion of the investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  Moderate or severe acute illness/infection (according to investigator judgment) on\n             the day of vaccination or febrile illness (temperature \u2265 100.4\u00b0F [\u2265 38.0\u00b0C]). A\n             prospective subject should not be included in the study until the condition has\n             resolved or the febrile event has subsided\n\n          -  Receipt of oral or injectable antibiotic therapy within 3 days prior to any blood\n             draw. Should a subject receive oral or injectable antibiotic therapy within 3 days\n             prior to any blood draw, the Investigator will postpone the blood draw until it has\n             been 3 days since the subject last received oral or injectable antibiotic therapy.\n             Postponement must still be within the timeframe for blood draw indicated in the Table\n             of Study Procedures, when possible\n\n          -  Identified as an Investigator or employee of the Investigator or study center with\n             direct involvement in the proposed study, or identified as an immediate family member\n             (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with\n             direct involvement in the proposed study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "56 Years"
        }, 
        "enrollment": {
            "#text": "301", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732627", 
            "org_study_id": "MET44", 
            "secondary_id": "U1111-1127-6804"
        }, 
        "intervention": [
            {
                "arm_group_label": "MenACYW Vaccine Group", 
                "description": "0.5 mL, Intramuscular", 
                "intervention_name": "MenACYW Conjugate Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Menomune\u00ae  A/C/Y/W 135 Vaccine Group", 
                "description": "0.5 mL, Subcutaneous", 
                "intervention_name": "Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined", 
                "intervention_type": "Biological", 
                "other_name": "Menomune\u00ae A/C/Y/W 135"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Meningitis", 
            "Meningococcal Meningitis", 
            "Menactra\u00ae", 
            "Menomune\u00ae   A/C/Y/W-135"
        ], 
        "lastchanged_date": "November 11, 2013", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofi.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chandler", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85224"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85251"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80239"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milford", 
                        "country": "United States", 
                        "state": "Connecticut", 
                        "zip": "06460"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edina", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55435"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63141"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Anderson", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29621"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murray", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84123"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84124"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "West Jordan", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84088"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22911"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older", 
        "overall_official": {
            "affiliation": "Sanofi Pasteur Inc.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Immunogenicity endpoints on serum bactericidal antibody titers for each meningococcal serogroup will be measured by serum bactericidal assay using human and rabbit complements", 
                "measure": "Percentages of Participants with Seroresponse in terms of functional antibodies to the meningococcal serogroups after Vaccination with either MenACYW conjugate or Menomune\u00ae Vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 30 post-vaccination"
            }, 
            {
                "description": "Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: fever (temperature), headache, malaise, and myalgia.", 
                "measure": "Number of Participants Reporting Solicited Injection Site Reactions, Solicited Systemic Reactions, Unsolicited Systemic Reactions, and Serious Adverse Events Occurring after vaccination with either MenACYW conjugate or Menomune\u00ae Vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 0 up to Day 30 post vaccination."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732627"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}